Wall Street's main indexes were little changed on Tuesday following post-election gains over the past few days.

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, is proud to announce an exciting new partnership with the Los Angeles Rams aimed at "Protecting the Rams House" ...

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax (NVAX – Research Report) today and set a price target of ...

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After ...

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...

Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...

NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...